Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.

Toshifumi TadaTakashi KumadaAtsushi HiraokaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi Nishimura Takeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataTakaaki TanakaHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiAtsushi NaganumaYohei KoizumiShinichiro NakamuraKouji JokoHiroko IijimaYoichi Hiasanull null

Published in: Cancer medicine (2022)

Atez/Bev can be used efficaciously and safely in spite of age in patients with unresectable HCC.

Keyphrases

middle aged
locally advanced
cross sectional
squamous cell carcinoma
clinical trial
radiation therapy
rectal cancer